

Myocardial Infarction - Pipeline Review, H1 2020

<https://marketpublishers.com/r/MCE8D8982C5EN.html>

Date: March 2020

Pages: 362

Price: US\$ 2,000.00 (Single User License)

ID: MCE8D8982C5EN

Abstracts

Myocardial Infarction - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H1 2020, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 17, 11, 51, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 2, 19 and 4 molecules, respectively.

Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA)

and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Myocardial Infarction - Overview

Myocardial Infarction - Therapeutics Development

Myocardial Infarction - Therapeutics Assessment

Myocardial Infarction - Companies Involved in Therapeutics Development

Myocardial Infarction - Drug Profiles

Myocardial Infarction - Dormant Projects

Myocardial Infarction - Discontinued Products

Myocardial Infarction - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Myocardial Infarction, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Myocardial Infarction - Pipeline by Actinogen Medical Ltd, H1 2020

Myocardial Infarction - Pipeline by Angion Biomedica Corp, H1 2020

Myocardial Infarction - Pipeline by Ankasa Regenerative Therapeutics Inc, H1 2020

Myocardial Infarction - Pipeline by Aposcience AG, H1 2020

Myocardial Infarction - Pipeline by Applied Therapeutics Inc, H1 2020

Myocardial Infarction - Pipeline by Aprogen Inc, H1 2020

Myocardial Infarction - Pipeline by APT Therapeutics Inc, H1 2020

Myocardial Infarction - Pipeline by AstraZeneca Plc, H1 2020

Myocardial Infarction - Pipeline by Athera Biotechnologies AB, H1 2020

Myocardial Infarction - Pipeline by Athersys Inc, H1 2020

Myocardial Infarction - Pipeline by Axolo Pharma Inc, H1 2020
Myocardial Infarction - Pipeline by Bayer AG, H1 2020
Myocardial Infarction - Pipeline by Bharat Biotech Ltd, H1 2020
Myocardial Infarction - Pipeline by Cadila Healthcare Ltd, H1 2020
Myocardial Infarction - Pipeline by CardioCreate Inc, H1 2020
Myocardial Infarction - Pipeline by Cardiol Therapeutics Inc, H1 2020
Myocardial Infarction - Pipeline by Cardior Pharmaceuticals GmbH, H1 2020
Myocardial Infarction - Pipeline by CeleCor Therapeutics Inc, H1 2020
Myocardial Infarction - Pipeline by Celixir Ltd, H1 2020
Myocardial Infarction - Pipeline by CellProthera SAS, H1 2020
Myocardial Infarction - Pipeline by CFM Pharma Holding BV, H1 2020
Myocardial Infarction - Pipeline by Cynata Therapeutics Ltd, H1 2020
Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc, H1 2020
Myocardial Infarction - Pipeline by Domainex Ltd, H1 2020
Myocardial Infarction - Pipeline by EndoProtech Inc, H1 2020
Myocardial Infarction - Pipeline by Ever Supreme Bio Technology Co Ltd, H1 2020
Myocardial Infarction - Pipeline by Evotec SE, H1 2020
Myocardial Infarction - Pipeline by EyeGene Inc, H1 2020
Myocardial Infarction - Pipeline by Faraday Pharmaceuticals Inc, H1 2020
Myocardial Infarction - Pipeline by General Regeneratives Shanghai Ltd, H1 2020
Myocardial Infarction - Pipeline by Generium, H1 2020
Myocardial Infarction - Pipeline by GNT Pharma Co Ltd, H1 2020
Myocardial Infarction - Pipeline by Hemostemix Inc, H1 2020
Myocardial Infarction - Pipeline by Honya Medical Inc, H1 2020
Myocardial Infarction - Pipeline by HUYA Bioscience International LLC, H1 2020
Myocardial Infarction - Pipeline by Idorsia Pharmaceutical Ltd, H1 2020
Myocardial Infarction - Pipeline by iHeart Japan Corp, H1 2020
Myocardial Infarction - Pipeline by InCarda Therapeutics Inc, H1 2020
Myocardial Infarction - Pipeline by Innolife Co Ltd, H1 2020
Myocardial Infarction - Pipeline by Inotrem SA, H1 2020
Myocardial Infarction - Pipeline by IPS Heart Inc, H1 2020
Myocardial Infarction - Pipeline by K-Stemcell Co Ltd, H1 2020
Myocardial Infarction - Pipeline by Kine Sciences, H1 2020
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
Myocardial Infarction - Pipeline by LTT Bio-Pharma Co Ltd, H1 2020
Myocardial Infarction - Pipeline by MandalMed Inc, H1 2020
Myocardial Infarction - Pipeline by Marizyme Inc, H1 2020
Myocardial Infarction - Pipeline by Mesoblast Ltd, H1 2020
Myocardial Infarction - Pipeline by MIFCOR Inc, H1 2020

Myocardial Infarction - Pipeline by MimeTech Srl, H1 2020
Myocardial Infarction - Pipeline by Mirae Cell Bio Co Ltd, H1 2020
Myocardial Infarction - Pipeline by New World Laboratories Inc, H1 2020
Myocardial Infarction - Pipeline by Novartis AG, H1 2020
Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H1 2020
Myocardial Infarction - Pipeline by OMEICOS Therapeutics GmbH, H1 2020
Myocardial Infarction - Pipeline by OP2 Drugs SAS, H1 2020
Myocardial Infarction - Pipeline by Opsona Therapeutics Ltd, H1 2020
Myocardial Infarction - Pipeline by OtiTopic LLC, H1 2020
Myocardial Infarction - Pipeline by Oxstem Ltd, H1 2020
Myocardial Infarction - Pipeline by Pharmahungary Group, H1 2020
Myocardial Infarction - Pipeline by Polyphor AG, H1 2020
Myocardial Infarction - Pipeline by Primary Peptides Inc, H1 2020
Myocardial Infarction - Pipeline by Quark Pharmaceuticals Inc, H1 2020
Myocardial Infarction - Pipeline by Qurgen Inc (Inactive), H1 2020
Myocardial Infarction - Pipeline by Reata Pharmaceuticals Inc, H1 2020
Myocardial Infarction - Pipeline by Recardio GmbH, H1 2020
Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2020
Myocardial Infarction - Pipeline by ResoTher Pharma ApS, H1 2020
Myocardial Infarction - Pipeline by Rubicon Biotechnology Inc, H1 2020
Myocardial Infarction - Pipeline by Sentan Pharma Inc, H1 2020
Myocardial Infarction - Pipeline by Serpin Pharma LLC, H1 2020
Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals Inc, H1 2020
Myocardial Infarction - Pipeline by SmartPharm Therapeutics Inc, H1 2020
Myocardial Infarction - Pipeline by Sorrento Therapeutics Inc, H1 2020
Myocardial Infarction - Pipeline by T&R Biofab Co Ltd, H1 2020
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co Ltd, H1 2020
Myocardial Infarction - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Myocardial Infarction - Pipeline by Techfields Pharma Co Ltd, H1 2020
Myocardial Infarction - Pipeline by Thrombolytic Science International LLC, H1 2020
Myocardial Infarction - Pipeline by Translational Sciences Inc, H1 2020
Myocardial Infarction - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2020
Myocardial Infarction - Pipeline by XBiotech Inc, H1 2020
Myocardial Infarction - Pipeline by Xcelthera INC, H1 2020
Myocardial Infarction - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020
Myocardial Infarction - Pipeline by Yuyu Pharma Inc, H1 2020
Myocardial Infarction - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2020
Myocardial Infarction - Dormant Projects, H1 2020
Myocardial Infarction - Dormant Projects, H1 2020 (Contd..1), H1 2020

Myocardial Infarction - Dormant Projects, H1 2020 (Contd..2), H1 2020
Myocardial Infarction - Dormant Projects, H1 2020 (Contd..3), H1 2020
Myocardial Infarction - Dormant Projects, H1 2020 (Contd..4), H1 2020
Myocardial Infarction - Dormant Projects, H1 2020 (Contd..5), H1 2020
Myocardial Infarction - Dormant Projects, H1 2020 (Contd..6), H1 2020
Myocardial Infarction - Dormant Projects, H1 2020 (Contd..7), H1 2020
Myocardial Infarction - Dormant Projects, H1 2020 (Contd..8), H1 2020
Myocardial Infarction - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Myocardial Infarction, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Actinogen Medical Ltd
Angion Biomedica Corp
Ankasa Regenerative Therapeutics Inc
Aposcience AG
Applied Therapeutics Inc
Aprogen Inc
APT Therapeutics Inc
AstraZeneca Plc
Athera Biotechnologies AB
Athersys Inc
Axolo Pharma Inc
Bayer AG
Bharat Biotech Ltd
Cadila Healthcare Ltd
CardioCreate Inc
Cardiol Therapeutics Inc
Cardior Pharmaceuticals GmbH
CeleCor Therapeutics Inc
Celixir Ltd
CellProthera SAS
CFM Pharma Holding BV

Cynata Therapeutics Ltd
Diffusion Pharmaceuticals Inc
Domainex Ltd
EndoProtech Inc
Ever Supreme Bio Technology Co Ltd
Evotec SE
EyeGene Inc
Faraday Pharmaceuticals Inc
General Regeneratives Shanghai Ltd
Generium
GNT Pharma Co Ltd
Hemostemix Inc
Honya Medical Inc
HUYA Bioscience International LLC
Idorsia Pharmaceutical Ltd
iHeart Japan Corp
InCarda Therapeutics Inc
Innolife Co Ltd
Inotrem SA
IPS Heart Inc
K-Stemcell Co Ltd
Kine Sciences
Lee's Pharmaceutical

I would like to order

Product name: Myocardial Infarction - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/MCE8D8982C5EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MCE8D8982C5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970